New Jersey Health Reporter
SEE OTHER BRANDS

Get your health and wellness news from New Jersey

New Jersey Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.

Press releases published on April 28, 2025

Mount Laurel Animal Hospital Fulfills Shelter Wish List for Homeward Bound on National Adopt a Shelter Pet Day

Mount Laurel Animal Hospital Fulfills Shelter Wish List for Homeward Bound on National Adopt a Shelter Pet Day

In a powerful display of compassion and community collaboration Mount Laurel Animal Hospital fulfills hundreds of items on a rescue’s wish list. MOUNT LAUREL, NJ, UNITED STATES, April 28, 2025 /⁨EINPresswire.com⁩/ -- In a powerful display of compassion …

Casey's Executive Interiors Expands into Education and Healthcare Furniture

Casey's Executive Interiors Expands into Education and Healthcare Furniture

Affordable, commercial-quality furniture and free office design services for schools and medical facilities in New Jersey. GREEN BROOK TOWNSHIP, NJ, UNITED STATES, April 28, 2025 /⁨EINPresswire.com⁩/ -- Casey's Executive Interiors, a leading office …

Stevie® Awards Recognize Premier NX For Digital Transformation Leadership

Stevie® Awards Recognize Premier NX For Digital Transformation Leadership

The Award Highlights The Company's Impact On Sales Enablement And Operations NEW PROVIDENCE, NJ, UNITED STATES, April 28, 2025 /⁨EINPresswire.com⁩/ -- Premier NX is proud to announce that it has been recognized in the annual Stevie® Awards for Sales …

Malka Shaw, LCSW, Launches Kesher Shalom Projects to Address Trauma, Antisemitism, and Mental Health

Malka Shaw, LCSW, Launches Kesher Shalom Projects to Address Trauma, Antisemitism, and Mental Health

Kesher Shalom equips professionals with tools to address trauma, antisemitism, and the psychological impact of propaganda, bias, and indoctrination. NUTLEY, NJ, UNITED STATES, April 28, 2025 /⁨EINPresswire.com⁩/ -- Malka Shaw, LCSW, a licensed trauma …

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a …

UK Company, Stablepharma Ltd, enters Phase 1 Clinical Trials with world-first Fridge-Free Tetanus & Diphtheria Vaccine

UK Company, Stablepharma Ltd, enters Phase 1 Clinical Trials with world-first Fridge-Free Tetanus & Diphtheria Vaccine

LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by …

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET1 imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide …

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

– Oral and poster presentations will highlight advancements from ElevateBio’s two business units: Life Edit, its gene editing and R…

IgA Nephropathy Foundation Celebrates 21 Years of Advocacy, Awareness, and Progress

IgA Nephropathy Foundation Celebrates 21 Years of Advocacy, Awareness, and Progress

Since May 14, 2004, the Foundation has dedicated itself to supporting patients, advancing research, and advocating for early diagnosis and treatment of IgAN. WALL TOWNSHIP, NJ, UNITED STATES, April 28, 2025 /⁨EINPresswire.com⁩/ -- The IgA Nephropathy …

ARCPOINT REPORTS 2024 YEAR END FINANCIAL RESULTS AND ANNOUNCES MANAGEMENT CHANGE

ARCPOINT REPORTS 2024 YEAR END FINANCIAL RESULTS AND ANNOUNCES MANAGEMENT CHANGE

Greenville, South Carolina, April 28, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) is pleased to report that it has filed its 2024 year end, audited Financial Statements and related Management Discussion and Analysis as …

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with …

Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025

Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025

NEW YORK, 28 avr. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour développer des thérapies cellulaires …

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Reflects business philosophy of commercial success through patient accessibility Recently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder …

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalability …

Arbor Biotechnologies to Present Foundational Data for PH1 and CNS Programs at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Arbor Biotechnologies to Present Foundational Data for PH1 and CNS Programs at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

-  Oral presentation to include preclinical data supporting the clinical advancement of ABO-101 for the treatment of primary hyperoxaluria type 1 - Four poster presentations collectively demonstrate advancement of company’s differentiated CNS gene editing …

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual …

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate …

Spur Therapeutics Announces Oral and Poster Presentations Highlighting Data from Clinical and Preclinical Programs at Upcoming ASGCT Annual Meeting

Spur Therapeutics Announces Oral and Poster Presentations Highlighting Data from Clinical and Preclinical Programs at Upcoming ASGCT Annual Meeting

LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share new data from its gene therapy programs in Gaucher disease, GBA1 Parkinson’s disease and adrenomyeloneuropathy in oral and poster presentations at the American …

Axovia Therapeutics Announces Three Upcoming Poster Presentations at ASGCT

Axovia Therapeutics Announces Three Upcoming Poster Presentations at ASGCT

LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, today announced that Co-Founder and Chief Scientific Officer, Dr. Victor Hernandez, …

Shape Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

Shape Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

SEATTLE, April 28, 2025 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader in RNA-based gene therapy, today announced the acceptance of multiple abstracts, including two oral presentations, at the upcoming 28th Annual Meeting of the American Society of Gene …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service